Ludwig Enterprises (Ludwig Enterprises) Total Payout Yield % : 0.00 (As of Jun. 04, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Ludwig Enterprises's current Total Payout Yield % is 0.00%.

Ludwig Enterprises Total Payout Yield % Historical Data

The historical data trend for Ludwig Enterprises's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Total Payout Yield % Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

Total Payout Yield %

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Payout Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Ludwig Enterprises's Total Payout Yield %

For the Medical Devices subindustry, Ludwig Enterprises's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ludwig Enterprises's Total Payout Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ludwig Enterprises's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Ludwig Enterprises's Total Payout Yield % falls into.

Ludwig Enterprises Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Ludwig Enterprises's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	21.0655075
	=	0.00%

Ludwig Enterprises's annualized Total Payout Yield % for the quarter that ended in Mar. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	0)	*	4	/	38.86625
	=	0.00%

Ludwig Enterprises Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Ludwig Enterprises Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.